Pharma Boom in Emerging Markets
While the pharmaceutical market for the US stagnates, IMS Health forecasts 14% to 15% growth in the so-called emerging markets, or what they call pharmerging markets. I think they need some help coming up with a better buzzword--something that rolls off the tongue more easily. Which syllable do you stress most? FAR-merging? How far is that merger? Who said anything about mergers? But I digress. The larger point still stands:
Rapid Expansion of "Pharmerging" Markets. The pharmerging markets of China, Brazil, India, South Korea, Mexico, Turkey and Russia are forecast to grow at a combined 14 - 15 percent pace to $105 - $115 billion. Along with the pharmaceutical industry's increased focus on these high-growth markets, these countries are benefiting from greater government spending on healthcare and broader public and private healthcare funding – which is driving greater access to, and demand for, innovative medicines.Related Post: Growing market for malaria drugs
2 comments:
CGD recently convened the Global Health Frontiers workshop to examine exactly this topic (if not the semantics). It will be interesting to read about their findings!
I know they'll be worth reading since the workshop is being led by Ruth Levine and Melinda Moree--two very smart and realistic thinkers in the field. Please let me know when the results are published.
Post a Comment